Biosergen AB (FRA:8N10) Other Financing: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8N10 Biosergen AB FRA:8N10
18 GF Score
Price €0.51
View Full Analysis

What is Biosergen AB Other Financing?

Biosergen AB FRA:8N10 18 Other Financing is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:8N10 with a GF Score™ of 18/100.

Biosergen AB's Other Financing for the three months ended in Dec. 2025 was €0.00 Mil.

Biosergen AB's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Biosergen AB Other Financing Historical Data

* Premium members only.

The historical data trend for Biosergen AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosergen AB Other Financing Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Biosergen AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:8N10
18GF Score
Biosergen AB FRA:8N10
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosergen AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.00 Mil mean?
Biosergen AB (FRA:8N10) has a Other Financing of €0.00 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Biosergen AB and its competitors.
Is Biosergen AB's Other Financing too high?
Biosergen AB's current Other Financing is €0.00 Mil. Overall, Biosergen AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biosergen AB's Other Financing compare to VRTX and REGN?
Biosergen AB's Other Financing of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Biosergen AB and its competitors. Biosergen AB's current Other Financing is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosergen AB stock overvalued right now?
Biosergen AB (FRA:8N10) has a current Other Financing of €0.00 Mil. The current Other Financing is €0.00 Mil. Biosergen AB's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Biosergen AB (FRA:8N10), the current Other Financing is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biosergen AB Business Description

Other Exchanges BIOSGN:Sweden
Address Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.
18GF Score

Get the complete analysis for FRA:8N10

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price